TORRENT PHARMACEUTICALS Financial Statement Analysis
|
||
The Revenues of TORRENT PHARMACEUTICALS have increased by 13.07% YoY .
The Earnings Per Share (EPS) of TORRENT PHARMACEUTICALS has increased by 33.03 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
TORRENT PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 500420|NSE : TORNTPHARM]
Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
---|---|---|---|---|---|
Revenues | ₹9,620 Cr | ₹8,508 Cr | ₹8,005 Cr | ₹7,939 Cr | ₹7,673 Cr |
Expenses | ₹6,796 Cr | ₹6,077 Cr | ₹5,524 Cr | ₹5,769 Cr | ₹5,696 Cr |
Operating Profit (Excl OI) | ₹2,824 Cr | ₹2,431 Cr | ₹2,480 Cr | ₹2,170 Cr | ₹1,976 Cr |
Other Income | ₹63 Cr | ₹197 Cr | ₹57 Cr | ₹121 Cr | ₹64 Cr |
Interest | ₹333 Cr | ₹255 Cr | ₹353 Cr | ₹451 Cr | ₹504 Cr |
Depreciation | ₹707 Cr | ₹662 Cr | ₹658 Cr | ₹654 Cr | ₹618 Cr |
Profit Before Tax | ₹1,847 Cr | ₹1,226 Cr | ₹1,526 Cr | ₹1,187 Cr | ₹562 Cr |
Profit After Tax | ₹1,245 Cr | ₹777 Cr | ₹1,252 Cr | ₹1,025 Cr | ₹436 Cr |
Consolidated Net Profit | ₹1,245 Cr | ₹777 Cr | ₹1,252 Cr | ₹1,025 Cr | ₹436 Cr |
Earnings Per Share (Rs) | ₹48.94 | ₹36.79 | ₹45.92 | ₹73.97 | ₹60.55 |
PAT Margin (%) | 9.92 | 7.63 | 5.11 | 8.41 | 6.85 |
ROE(%) | 25.38 | 20.50 | 13.18 | 23.49 | 21.47 |
ROCE(%) | 24.28 | 20.32 | 14.35 | 17.62 | 15.28 |
Total Debt/Equity(x) | 0.57 | 0.85 | 0.68 | 0.83 | 1.21 |
Key Financials |
||
Market Cap | : | ₹ 107,590.9 Cr |
Revenue (TTM) | : | ₹ 11,516.0 Cr |
Net Profit(TTM) | : | ₹ 1,911.0 Cr |
EPS (TTM) | : | ₹ 56.5 |
P/E (TTM) | : | 56.3 |
Industry Peers & Returns | 1W | 1M | 1Y |
TORRENT PHARMACEUTICALS | 1.4% | 1.3% | 17% |
SUN PHARMACEUTICAL INDUSTRIES | 1.6% | -2.9% | 17.2% |
DIVIS LABORATORIES | 1.5% | 10.4% | 51.9% |
CIPLA | 2.3% | 1.9% | 2.8% |
DR REDDYS LABORATORIES | 5.7% | 14.1% | 15.2% |
MANKIND PHARMA | 0.2% | -2.4% | 12.5% |
ZYDUS LIFESCIENCES | 5.1% | 10.9% | -4.4% |
LUPIN | 2% | -2.2% | 27.9% |
AUROBINDO PHARMA | 1.5% | -0.2% | -3.3% |
TORRENT PHARMACEUTICALS Revenues
[BOM: 500420|NSE : TORNTPHARM]
Y-o-Y | 13.07 % |
5 Yr CAGR | 5.82 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹9,620 Cr | 13.07 | |
Mar2023 | ₹8,508 Cr | 6.29 | |
Mar2022 | ₹8,005 Cr | 0.82 | |
Mar2021 | ₹7,939 Cr | 3.47 | |
Mar2020 | ₹7,673 Cr | - |
TORRENT PHARMACEUTICALS Operating Profit
[BOM: 500420|NSE : TORNTPHARM]
Y-o-Y | 16.15 % |
5 Yr CAGR | 9.33 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹2,824 Cr | 16.15 | |
Mar2023 | ₹2,431 Cr | -1.97 | |
Mar2022 | ₹2,480 Cr | 14.27 | |
Mar2021 | ₹2,170 Cr | 9.81 | |
Mar2020 | ₹1,976 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 2.69 % |
5 Yr CAGR | 3.32 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 29.35% | 2.69 | |
Mar2023 | 28.58% | -7.75 | |
Mar2022 | 30.98% | 13.31 | |
Mar2021 | 27.34% | 6.13 | |
Mar2020 | 25.76% | - |
TORRENT PHARMACEUTICALS Profit After Tax
[BOM: 500420|NSE : TORNTPHARM]
Y-o-Y | 60.22 % |
5 Yr CAGR | 29.98 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹1,245 Cr | 60.22 | |
Mar2023 | ₹777 Cr | -37.92 | |
Mar2022 | ₹1,252 Cr | 22.17 | |
Mar2021 | ₹1,025 Cr | 134.88 | |
Mar2020 | ₹436 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 30.01 % |
5 Yr CAGR | 9.70 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 9.92 % | 30.01 | |
Mar2023 | 7.63 % | 49.32 | |
Mar2022 | 5.11 % | -39.24 | |
Mar2021 | 8.41 % | 22.77 | |
Mar2020 | 6.85 % | - |
TORRENT PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 500420|NSE : TORNTPHARM]
Y-o-Y | 33.03 % |
5 Yr CAGR | -5.18 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹49 | 33.03 | |
Mar2023 | ₹37 | -19.88 | |
Mar2022 | ₹46 | -37.92 | |
Mar2021 | ₹74 | 22.16 | |
Mar2020 | ₹61 | - |
TORRENT PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 500420|NSE : TORNTPHARM]
Y-o-Y | 19.49 % |
5 Yr CAGR | 12.27 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 24.28% | 19.49 | |
Mar2023 | 20.32% | 41.60 | |
Mar2022 | 14.35% | -18.56 | |
Mar2021 | 17.62% | 15.31 | |
Mar2020 | 15.28% | - |
TORRENT PHARMACEUTICALS Share Price vs Sensex
Current Share Price | : | ₹3,179.4 |
Current MarketCap | : | ₹ 107,590.9 Cr |
Updated EOD on | : | Jun 09,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
TORRENT PHARMACEUTICALS | 1.4% |
1.3% |
17% |
SENSEX | 1.3% |
2.6% |
7.8% |
TORRENT PHARMACEUTICALS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE ALLCAP | 6.4% | 8.9% | 7.5% |
BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
BSE MOMENTUM INDEX | 3.7% | 8.4% | -2.1% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY200 MOMENTUM 30 | 3.3% | 8.5% | -11.8% |
NIFTY100 ALPHA 30 | 3.2% | 7.7% | -10.8% |
NIFTY 500 EQUAL WEIGHT | 2.8% | 13.3% | 8.2% |
NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | 2.8% | 10.5% | NA |
NIFTY NEXT 50 | 2.7% | 9.7% | -2.5% |
You may also like the below Video Courses
FAQ about TORRENT PHARMACEUTICALS Financials
How the annual revenues of TORRENT PHARMACEUTICALS have changed ?
The Revenues of TORRENT PHARMACEUTICALS have increased by 13.07% YoY .
How the Earnings per Share (EPS) of TORRENT PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of TORRENT PHARMACEUTICALS has increased by 33.03 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs